A detailed history of Morgan Stanley transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,537,296 shares of RNA stock, worth $41.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,537,296
Previous 1,490,743 3.12%
Holding current value
$41.3 Million
Previous $13.5 Million 190.79%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$9.16 - $25.52 $426,425 - $1.19 Million
46,553 Added 3.12%
1,537,296 $39.2 Million
Q4 2023

Feb 13, 2024

BUY
$4.87 - $9.37 $1.62 Million - $3.12 Million
333,161 Added 28.78%
1,490,743 $13.5 Million
Q3 2023

Nov 15, 2023

BUY
$6.3 - $11.35 $371,618 - $669,502
58,987 Added 5.37%
1,157,582 $7.39 Million
Q2 2023

Aug 14, 2023

SELL
$10.62 - $17.34 $1.63 Million - $2.67 Million
-153,867 Reduced 12.29%
1,098,595 $12.2 Million
Q1 2023

May 15, 2023

BUY
$15.35 - $25.65 $3.49 Million - $5.84 Million
227,610 Added 22.21%
1,252,462 $19.2 Million
Q4 2022

Feb 14, 2023

BUY
$10.06 - $22.66 $9.5 Million - $21.4 Million
944,272 Added 1171.84%
1,024,852 $22.7 Million
Q3 2022

Nov 14, 2022

SELL
$15.46 - $23.43 $829,413 - $1.26 Million
-53,649 Reduced 39.97%
80,580 $1.32 Million
Q2 2022

Oct 27, 2022

BUY
$11.18 - $20.5 $277,901 - $509,568
24,857 Added 22.73%
134,229 $1.95 Million
Q2 2022

Aug 15, 2022

BUY
$11.18 - $20.5 $277,901 - $509,568
24,857 Added 22.73%
134,229 $1.95 Million
Q1 2022

Oct 27, 2022

SELL
$14.2 - $23.78 $352,969 - $591,099
-24,857 Reduced 18.52%
109,372 $2.02 Million
Q1 2022

May 13, 2022

BUY
$14.2 - $23.78 $490,681 - $821,717
34,555 Added 46.19%
109,372 $2.02 Million
Q4 2021

Feb 14, 2022

SELL
$20.4 - $28.66 $979,607 - $1.38 Million
-48,020 Reduced 39.09%
74,817 $1.78 Million
Q3 2021

Nov 15, 2021

BUY
$18.16 - $25.21 $2.23 Million - $3.1 Million
122,837 New
122,837 $3.03 Million

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.4B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.